Nxera Pharma
Tracked across 4 events · 27 articles · First seen Apr 20, 2026 · Last active Jun 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Nxera Pharma Co., Ltd. announced on June 10, 2026, that it has joined OpenFold, a non-profit AI research consortium dedicated to developing open-source AI software tools for biology and drug discovery. This move aligns with…
Impact: Nxera Pharma joined the OpenFold consortium to enhance its AI-enabled drug discovery capabilities, particularly for GPCR targets, aligning with its strategy to improve R&D productivity and achieve its 2030 vision. This move is expected to strengthen its competitive position in the biopharmaceutical market.
Jun 10, 2026 · 9 articles
Regulatory
Santhera Pharmaceuticals announced that its drug AGAMREE has received Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation from South Korea's South Korea — Ministry of Food and Drug Safety for…
Impact: Nxera Pharma holds exclusive rights to AGAMREE in Japan, South Korea, Australia, and New Zealand, and plans to submit a Marketing Authorization Application in South Korea during 2026. This designation will accelerate the review process for AGAMREE.
Jun 02, 2026 · 6 articles
100
Nxera Pharma joined consortium OpenFoldNxera Pharma joins...
80
Nxera Pharma plans to submitAGAMREE receives South...
NEWSDESK
Track Nxera Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard